1
Jun 2026
Justicia carnea extract alleviates oxidative stress in pancreatitis
Chronic pancreatitis is an inflammatory disease and is difficult to manage despite advancements in medical science.
Stay Informed!
1
Jun 2026
Hypoxia-gated AAV enables targeted treatment for advanced NSCLC
Adeno‑associated virus (AAV) vectors offer safety and durable expression but lack tumor specificity. This hypothesis proposes an NSCLC‑directed, hypoxia‑responsive AAV platform that integrates MGS4 peptide‑guided capsid targeting with dual hypoxia‑responsive element (HRE)‑gated promoters driving Q‑CXCL9‑Fc (chemokine) and miR‑30‑based shRNA against mesothelin (MSLN).
1
Jun 2026
Mesenchymal drift may explain how aging cells lose their identity
Mesenchymal drift may help explain how cells lose stable identity and acquire pro-fibrotic, inflammatory mesenchymal traits during aging. The review proposes MD as a unifying framework that links multiple hallmarks of aging and highlights partial reprogramming as a potential, but still preclinical, way to counteract this process.
1
Jun 2026
New T-cell engager therapy shows effectiveness in advanced solid tumors
A team led by researchers from the National Center for Tumor Diseases (NCT/UCC) Dresden at the Carl Gustav Carus University Hospital (UKD) and the Carl Gustav Carus Faculty of Medicine at the TUD Dresden University of Technology will present clinical results for the first time on May 31, 2026, at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) regarding a new cancer immunotherapy for the treatment of advanced tumors.
1
Jun 2026
The right seafood choices can help diets meet health and climate goals
Fish can support healthy and sustainable diets, especially when it replaces red and processed meat rather than adding to overall animal-food intake. However, its environmental value depends on species, production system, supply chain, local dietary patterns, and the scale of greenhouse gas reductions required.
31
May 2026
Higher-dose ocrelizumab depletes more B cells but does not slow MS progression
Higher-dose ocrelizumab produced greater peripheral B-cell depletion than the approved 600 mg regimen in two phase 3b trials of relapsing and primary progressive multiple sclerosis. However, the higher doses did not significantly delay disability progression, supporting the 600 mg dose as the current standard regimen with a favorable benefit-risk profile.
31
May 2026
Novel PRRT approach shows promise in advanced neuroendocrine tumors
A new type of peptide receptor radionuclide therapy (PRRT) appears to be safe in metastatic neuroendocrine tumor patients who have exhausted conventional treatment options.
31
May 2026
Why new Alzheimer’s drugs are dividing regulators worldwide
The Lancet World Report examines why regulators in the US, UK, and Europe have reached different decisions on new amyloid-targeting Alzheimer’s drugs despite evidence that they can modestly slow clinical decline. It highlights the unresolved balance among benefits, safety risks, costs, access, and the need for broader, earlier, and more patient-centered treatment strategies.
31
May 2026
New PET imaging approach may enable early CTE diagnosis
A first-in-class PET imaging approach can accurately detect a biomarker for chronic traumatic encephalopathy (CTE), a devastating neurodegenerative disease associated with repeated head impact.
31
May 2026
Predictive model helps tailor PSMA therapy for prostate cancer patients
A new machine-learning approach for prostate-specific membrane antigen (PSMA) treatment of metastatic castration-resistant prostate cancer (mCRPC) could estimate radiation dose to tumors and healthy organs before therapy begins.
